Wells Fargo raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps an Overweight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care initiated with a Neutral at UBS
- Hold Rating for Sabra Healthcare REIT Amidst Balanced Valuation and Strategic Challenges
- Sabra Health Care REIT Reports Strong Q3 2025 Results
- Sabra Healthcare REIT’s Optimistic Earnings Call Analysis
- Sabra Healthcare REIT: Balancing Strong FAD Performance with Capital Cost Challenges